跳至主要内容
临床试验/CTRI/2008/091/000117
CTRI/2008/091/000117已完成3 期

A randomized double blind study of efficacy of Lactobacillus brevis CD2 lozenges in preventing radiation and chemotherapy induced oral mucositis in head and neck cancer.

CD Pharma India Pvt. Ltd. C 1/53, Ist floor, SDA, New Delhi-110016, Tel.01141759898, Fax. 011417598940 个研究点目标入组 200 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Inclusion Criteria
  • 1.Age between 18 and 70 years.
  • 2.Karnofsky Performance Score ≥ 70%.
  • 3.Confirmed histological diagnosis of cancer of head and/or neck area.
  • 4.Patient not previously treated with chemotherapy and/or radiotherapy except the patients who have received neoadjuvant chemotherapy for current head and neck cancer.
  • 5.Patients eligible to receive chemotherapy and/or radiotherapy.
  • 6.Concomitant co morbid condition if present, controlled by medicines.
  • 7.No distant metastasis.
  • 8.Normal bone marrow functions ANC (Absolute neutrophil count) ≥1500/cmm, platelets counts  1, 00,000/cmm).
  • 9.Serum creatinine<1.8mg/dl.
  • 10.Total bilirubin=< 2mg/dl.
  • 11.Liver enzymes within three times of normal limit.
  • 12.Expected survival > 6 months.
  • 13.Planning to receive a total radiation dose &#8805; 5500 cGy, administered in a single daily fraction of 180 - 220 cGy (5 days a week) or twice daily fractions of 110 - 150 cGy.

排除标准

  • 1.Patients weighing less than 35 kgs.
  • 2.Pregnant women and lactating mothers.
  • 3.Patients with history of AIDS, Hepatitis B/ C.
  • 4.Patients who have taken any other investigational product in last 4 weeks.
  • 5.Patients having untreated symptomatic dental infection.
  • 6.Patients with WHO Grade 3 or 4 oral Mucositis.
  • 7.Other serious concurrent illness.
  • 8.History of Insulin Dependent Diabetes Mellitus.
  • 9.Inconclusive histological diagnosis.
  • 10.Patients on anticancer antibiotics.
  • 11.Patients with signs and symptoms of systemic infections.
  • 12.Patient?s refusal to sign informed consent.

研究者

发起方
CD Pharma India Pvt. Ltd. C 1/53, Ist floor, SDA, New Delhi-110016, Tel.01141759898, Fax. 01141759894

相似试验